Novalis LifeSciences Launches its First Life Science Investment Fund with $85 Million

Novalis LifeSciences, an investment and advisory firm for the Life Science industry, announced today that it has raised $85M in capital for its first fund - Novalis LifeSciences Investments I, L.P.

Novalis LifeSciences is focused on highly innovative Life Science companies. Marijn E. Dekkers, founder and chairman, said: “This first fund is a growth-oriented fund that will invest in 8-12 companies that are commercializing breakthrough technologies in various segments of the Life Science industry. This includes drug discovery, life science tools, genomics, synthetic biology, diagnostics, and agricultural biotechnology – all areas with huge unmet needs and exciting opportunities for investors”.

Novalis' website lists seven companies in its portfolio. The companies include: BioQ Pharma, Cereval, and Ginkgo Bioworks.